Merck & Co., Inc. (ETR:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 171.37B |
| Revenue (ttm) | 59.14B |
| Net Income (ttm) | 16.13B |
| Shares Out | n/a |
| EPS (ttm) | 6.36 |
| PE Ratio | 10.62 |
| Forward PE | 8.46 |
| Dividend | 2.93 (4.34%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 5,194 |
| Average Volume | 4,704 |
| Open | 66.70 |
| Previous Close | 66.60 |
| Day's Range | 66.60 - 68.10 |
| 52-Week Range | 65.50 - 125.60 |
| Beta | 0.44 |
| RSI | 37.05 |
| Earnings Date | Apr 24, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the America...
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH)...
Decoding Merck & Co's Options Activity: What's the Big Picture?
Whales with a lot of money to spend have taken a noticeably bullish stance on Merck & Co . Looking at options history for Merck & Co (NYSE: MRK) we detected 18 trades. If we consider the specifics of...
Merck says late-stage trial for Keytruda regimen hit main goal in ovarian cancer
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L1 KEYTRUDA ® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first im...
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer.
From Cancer Drugs To Cosmetics: A Cash-strapped Company's Makeover Story
The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs Key Takeaways: Kintor Pharma is shifting ...
FDA Approves Merck’s WELIREG (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved WELIREG (belzutifan), Merck’s oral hypoxia-inducible f...
FDA Approves Merck's WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG PPGL FDA Approval News Release.
Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript)
Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?
Incannex Healthcare Inc (NASDAQ: IXHL) shares surged 876% to 83 cents on Wednesday after the company announced the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA trial fo...
Merck wins FDA label expansion for Welireg in neuroendocrine tumors
US FDA expands use of Merck's cancer drug for adrenal gland tumors
The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two types adrenal gland tumors.
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Germany's Merck drops China surcharge on orders after US-China tariff deal
German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China following the U.S.-China agreement to pause sky-high tariffs on each other, the com...
Tech sector leads: Nvidia and Amazon surge amidst healthcare tumble
Sector Overview The stock market is exhibiting diverse patterns today, with notable sector-specific performance highlighting varying investor outlooks. Technology Storms Ahead: The technology sector i...
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research across more than 25 types of cancer and multiple treatment settings from the company’s broad and d...
Research on Novel Treatment Approaches and Scientific Advances From Merck's Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research across more than 25 types of cancer and multiple trea...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Stocks making the biggest moves midday: Amazon, Alibaba, Merck, Five Below, Nike and more
These are the stocks posting the largest moves in midday trading.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.